The Dose Podcast- Episode 4 "PAN-TB and Novel Regimen Development"

 

Episode 4 of the WGND's podcast series, The Dose, is now available for streaming. In this episode join our moderator, Shobha Shukla, as she speaks with TB regimen development experts Dr. Debra Hanna and Dr. Robert Bates on the topic of the PAN-TB collaboration and novel regimen development. The PAN-TB collaboration of philanthropic, non-profit, and private sector organizations supported by the Bill & Melinda Gates Foundation strives to accelerate the development of shorter, safer, and affordable TB therapy with minimal existing drug resistance. 

The Dose Podcast: Episode 3 "Shortening TB Treatment & TBTC Study 31"

The Dose: Episode 3 "Shortening TB Treatment & TBTC Study 31" 

On World TB Day 2021, the Stop TB Partnership Working Group on New TB Drugs is proud to present the latest episode of The Dose podcast. The third episode will focus on the challenges of shortening DS-TB treatment and the results from the U.S. CDC TBTC Study 31 / A5449. In this episode, we address the obstacles that have previously prevented successful identification of shorter treatments for DS-TB and what the results from TBTC Study 31 could mean for future TB treatment.

Metformin

Submitted by zaidtanvir on

Metformin is an US FDA-approved drug that is currently a first-line treatment for type 2 diabetes. It is currently under investigation as a TB/HIV host-directed therapy in a Phase II open-label study at Aurum Institute. 

Metformin treatment has shown to reduce tissue pathology and inflammatory cytokines in mice (Singhal et al. Sci Translat Med 2014)

Phase 2: IMPACT-TB Safety, Pharmacokinetics & Hematologic Effect of Imatinib

Submitted by zaidtanvir on

This study will evaluate the safety, pharmacokinetics, and effects of imatinib on myelopoiesis in adults when given with and without isoniazid and rifabutin.

Participants will be enrolled into one of two cohorts. In Cohort 1, participants will be enrolled in a dose-escalating fashion to receive one of four doses of imatinib alone for 14 days, followed by imatinib in combination with rifabutin and isoniazid for another 14 days.

Imatinib

Submitted by zaidtanvir on

Imatinib is an FDA-approved oral medicine that is currently used to treat cancer. Imatinib is an antineoplastic agent that inhibits the Bcr-Abl fusion protein tyrosine kinase, an abnormal enzyme produced by chronic myeloid leukemia cells that contain the Philadelphia chromosome. It is sold under the name "Glivec". 

Imatinib is currently under investigation as a host-directed therapy for individuals with latent TB infection. 

Rifafour

Submitted by zaidtanvir on

Rifafour is a fixed-dose combination of the following four active TB drugs: 

Rifampicin 150 mg

lsoniazid 75 mg

Pyrazinamide 400 mg

Ethambutol HCI 275 mg

This regimen is considered the standard approved treatment for drug-sensitive Tuberculosis. 

Pages

Subscribe to Working Group for New TB Drugs RSS